证券代码：300723 证券简称：一品红 参与单位名 深圳市森瑞投资管理有限公司夏翔，广东邦政资产管理有限公司熊 称及人员姓 政，深圳市前海德毅资产管理有限公司彭得魁，珠海横琴麒涵基金管 名 理有限公司梁宏杰、甘梁乐斌，广东银石投资有限公司张玉玲，广州 聚添成投资管理有限公司阮锡满，广东潮金投资基金管理有限公司彭 兴、陈荣民，善水源（横琴）资产管理有限公司曾飞飞，广东金羊基 金管理有限公司张鸿亮，广州智品隆私募证券投资基金管理有限公司 桂习铭、许敬文，广州雪球投资管理有限公司沈中芳，广州敦然投资 管理有限公司王鹏，广州市乾元资产管理有限公司庄梓轩，华美国际 投资集团有限公司赖菲虹，广州同泽投资管理有限公司廖翊，广东金 灿私募基金管理有限公司黄伟坤，深圳崇楷基金管理有限公司向明， 海通证券广东分公司蔡昭鹏等 1 一品红药业股份有限公司 投资者关系活动记录表 编号：2021-005 | --- | --- | --- | --- | |------------|---------------------------|----------------------------|-------| | | | | | | ...

证券代码：300723 证券简称：一品红 1 一品红药业股份有限公司 投资者关系活动记录表 编号：2021-007 | --- | --- | --- | |-----------------|----------------------------|----------------------------------------------------------------| | | | | | 投 资者 关系 | √特定对象调研 | □分析师会议 | | 活动类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参 与单 位名 | 胡博新 | 东兴证券股份有限公司 医药行业首席分析师 | | 称 及人 员姓 | | | | 名 | | | | 时间 2021 | 年 8 | 下午 3:00 | | 地点 公司会议室 | | | | 上 市公 司接 | | 副总经理兼董事会秘书：谢小华； | | 待人员姓名 | 总裁助理：郭志龙； | | | | 分析评估部负责人：许光凯； | | | | ...

证券代码：300723 证券简称：一品红 编号：2021-003 1 一品红药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|---------------------------------------------------------|-----------------------------------------------------------------| | | | | | 投资者关系 | √特定对象调研 □分析师会议 | | | 活动类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名 | 中航证券研究所 | 沈文文 医药行业首席分析师 | | 称及人员姓 | | | | 名 | | | | | | | | 时间 2021 | 年 7 月 30 日 | 上午 10:00 | | 地点 公司会议室 | | | | 上市公司接 待人员姓名 | 副总经理兼董事会秘书：谢小华 投资者关系高级总 ...

证券代码：300723 证券简称：一品红 1 一品红药业股份有限公司 投资者关系活动记录表 编号：2021-010 | --- | --- | --- | --- | |-------------------|----------------------------------------------|------------------------------------------------------|--------------------------------------------------| | | | | | | 投资者关系 | √特定对象调研 □分析师会议 | | | | 活动类别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名 | 信达证券股份有限公司 | 医药行业首席分析师 周平 | | | 称及人员姓 | 德邦证券股份有限公司 | 固定收益组分析师 陈剑涛 | | | 名 | 德邦证券股份有限公司 | 固定收益组分析师 | 徐亮 | | ...

Financial Performance - The company's revenue for Q3 2022 was ¥709,752,729.54, an increase of 1.39% year-on-year, while the revenue for the first three quarters was ¥1,614,859,689.70, a decrease of 2.32% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥111,360,455.49, a decrease of 34.62% year-on-year, and for the first three quarters, it was ¥265,963,921.46, down 7.75% year-on-year[6]. - The company reported a revenue of ¥1,614,859,689.70 for the year-to-date, a decrease of 2.32% compared to ¥1,653,196,227.48 in the same period last year[24]. - Operating income increased by 153.55% to ¥52,414,220.98, mainly from government subsidies unrelated to daily operations[28]. - Total operating revenue for the current period is CNY 1,614,859,689.70, a decrease of 2.3% from CNY 1,653,196,227.48 in the previous period[62]. - Net profit for the current period is CNY 246,741,931.70, a decrease of 6.6% compared to CNY 264,424,910.75 in the previous period[65]. - Comprehensive income attributable to the parent company is CNY 265,963,921.46, down from CNY 288,298,552.64 in the previous period[67]. Cash Flow and Assets - The company achieved a net cash flow from operating activities of ¥316,284,117.52 for the first three quarters, an increase of 30.03% year-on-year[6]. - The company’s cash flow from operating activities showed a significant increase, reflecting improved operational efficiency[27]. - Cash inflow from operating activities totaled ¥1,935,058,574.66, up from ¥1,894,283,154.74, indicating a rise of about 2.2%[69]. - Cash outflow from operating activities decreased to ¥1,618,774,457.14 from ¥1,651,041,789.90, showing a reduction of approximately 2%[69]. - The ending balance of cash and cash equivalents was ¥529,544,018.00, slightly up from ¥512,239,494.01[72]. - The company received ¥80,800,161.93 in tax refunds, a substantial increase from ¥15,174,701.04 in the previous period[69]. - The company achieved a significant increase in cash management assets, with financial assets measured at fair value rising by 342.23% to ¥66,453,720.64[20]. Research and Development - R&D expenses increased by 17.57% to ¥117,175,604.46, reflecting the company's ongoing commitment to enhancing its research projects[24]. - The company has received 11 new drug registration approvals and 1 raw material drug passed CDE technical review, which is expected to positively impact revenue[20]. - The company’s collaboration with Arthrosi on the gout drug AR882 has shown promising results in preclinical studies, indicating good efficacy and tolerability in patients with varying degrees of renal impairment[19]. - The company is facing risks in drug development due to high investment and long cycles, despite efforts to enhance R&D capabilities[51]. Inventory and Assets Management - The company’s inventory increased by 30.80% to ¥150,378,083.75, attributed to growth in pharmaceutical manufacturing sales and successful bidding in centralized procurement[20]. - The company’s fixed assets rose by 79.32% to ¥284,584,688.60, mainly due to the completion of several engineering projects[20]. - As of September 30, 2022, the company's total assets reached CNY 4.1 billion, an increase from CNY 3.7 billion at the beginning of the year[55]. - The company's current assets totaled CNY 1.62 billion, up from CNY 1.56 billion at the beginning of the year[55]. - The company's inventory increased to CNY 150.38 million from CNY 114.97 million, reflecting a growth of 30.8%[55]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 10,413[32]. - The company’s net profit attributable to the parent company increased, leading to a 20.04% rise in undistributed profits to ¥1,253,961,501.09[24]. - Total equity attributable to shareholders of the parent company rose to CNY 2,051,629,736.76, an increase of 9.4% from CNY 1,874,311,657.47[61]. - Minority interests increased to CNY 156,376,171.50 from CNY 144,071,264.85, reflecting a growth of 8.9%[61]. Financing Activities - Cash outflow from financing activities totaled ¥1,037,460,285.45, a 112.51% increase compared to the previous year, mainly due to higher cash payments for bank loan repayments[28]. - The company repaid bank loans amounting to ¥905,000,000.00, a 212.07% increase year-on-year[28]. - Cash inflow from financing activities amounted to ¥1,200,119,340.00, compared to ¥1,062,519,636.97, reflecting an increase of about 13%[72]. Governance and Corporate Actions - The company completed the repurchase and cancellation of 592,200 restricted shares due to unmet performance assessment requirements[39]. - The company’s board meetings have consistently approved significant financial and operational decisions, reflecting strong governance practices[47]. - The company completed the equity transfer of Guangdong Pingsheng Pharmaceutical Co., making it a wholly-owned subsidiary after signing relevant agreements with partners[49]. - The company invested CNY 19.8 million to acquire land use rights for a raw material drug production base in Guangdong Province[50].

证券代码：300723 证券简称：一品红 公告编号：2022-094 债券代码：123098 债券简称：一品转债 一品红药业股份有限公司 关于参加 2022 年广东辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，一品红药业股份有限公司（以下简称 "公司"）将参加由广东证监局和广东上市公司协会共同举办的"2022 年广东上市 公司投资者网上集体接待日活动"。现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景•路演天下"（http://rs.p5w.net）参与公司 本次投资者网上接待日活动。网上互动交流时间为 2022 年 9 月 22 日（星期四） 下午 15:50-16:50。 届时公司董事长兼总经理李捍雄先生，财务总监张辉星先生和董事会秘书张 明渊先生将通过网络在线方式，与投资者就公司治理、经营情况及发展战略等问 题进行沟通与交流，欢迎广大投资者积极参与。 特此公告。 一品红药业股份有限公司董事会 2022 年 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[22]. - The net profit attributable to shareholders was RMB 300 million, up 20% compared to the same period last year[22]. - The company's operating revenue for the reporting period was ¥905,106,960.16, a decrease of 5.04% compared to the same period last year[33]. - Net profit attributable to shareholders was ¥154,603,465.97, representing an increase of 31.06% year-on-year[33]. - The net cash flow from operating activities increased by 139.93% to ¥174,436,367.45 compared to the previous year[33]. - Basic and diluted earnings per share were both ¥0.5366, reflecting a growth of 31.07% from the previous year[36]. - The company reported a revenue of 876 million yuan for pharmaceutical manufacturing products, representing a year-on-year growth of 5.06%[57]. - The company's chronic disease drug revenue was approximately 305 million yuan, a year-on-year decrease of 18.31%[66]. - The company’s revenue from children's medicine reached CNY 527.29 million, a year-on-year increase of 19.37%[89]. Research and Development - The company plans to invest RMB 200 million in R&D for new drug development in the next fiscal year, focusing on chronic kidney disease treatments[22]. - R&D investment increased by 33.13% year-on-year, reaching approximately 70.068 million yuan in the first half of 2022[76]. - The company has established multiple technical innovation platforms for pediatric and chronic disease drugs[68]. - The company has established a new gene engineering vaccine R&D pilot and industrialization platform, focusing on recombinant protein nanoparticle vaccines using the BEVS technology, which is the first of its kind in China[72]. - The company has established multiple specialized R&D centers, including those for innovative drugs and biological vaccines, enhancing its pharmaceutical R&D capabilities[76]. - The company is focused on developing high-end sustained-release formulations and original innovative drugs to enhance its core competitiveness[101]. Market Expansion and Strategy - The company announced plans for market expansion into Southeast Asia, aiming to establish a presence in three new countries by the end of 2023[22]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[22]. - The company has expanded its market presence by developing approximately 5,310 new hospital terminals, including 1,138 secondary and higher-level hospitals[90]. - The company aims to enhance its market presence through strategic recommendations and adherence to clinical guidelines[65]. - The company is actively pursuing collaborations and partnerships to enhance its R&D capabilities and market presence[97]. Product Development and Pipeline - The company has 22 registered pediatric drug products covering over 70% of pediatric diseases, with 12 pediatric drugs and 5 vaccines currently in development[58]. - The newly approved pediatric drugs include "Carbocisteine Oral Solution" and "Oseltamivir Phosphate Capsules" which address urgent clinical needs[58]. - The company has 44 registered chronic disease drug approvals, with 24 projects under research, most having exclusive patents and unique therapeutic advantages[66]. - The innovative drug AR882 for hyperuricemia and gout has shown promising results in clinical trials, with 95% of patients achieving serum uric acid levels below 5 mg/dL at a 50 mg dosage[70]. - The company has received approval for two pediatric drug products: "Carbocisteine Oral Solution" and "Oseltamivir Phosphate Capsules"[98]. Regulatory and Market Risks - The company has identified several risks, including regulatory changes and market competition, and has outlined corresponding mitigation strategies[5]. - The government has emphasized improving chronic disease prevention and treatment services, which supports the company's strategic focus on chronic disease management[53]. - The pharmaceutical manufacturing industry is experiencing growth, with a 0.6% increase in production year-on-year for the first half of 2022[47]. Financial Management and Investments - The company will not distribute cash dividends or issue bonus shares for the current fiscal year, focusing on reinvestment[6]. - A total of 592,200 restricted stocks were repurchased and canceled due to unmet performance conditions, accounting for 0.21% of the total share capital[31]. - The company has made a significant equity investment of CNY 49,880,660.00 in Guangdong South China Vaccine Co., holding a 6.25% stake[141]. - The total amount of financial assets measured at fair value is CNY 161,092,532.99, with no changes in fair value gains or losses during the reporting period[145]. - The company has reported a total of 85,711.97 million yuan in investments in short-term bank financial products during the reporting period[182]. Subsidiary Performance - The company has a subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., with total assets of 1,031,117,094.94 yuan and net profit of 357,093,395.97 yuan[188]. - Another subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., reported a net loss of 7,719,202.36 yuan[188]. - The overall performance of subsidiaries indicates a mixed outlook, with some achieving significant revenue growth while others face profitability challenges[194].

Financial Performance - The company's revenue for Q1 2022 was CNY 515.71 million, a slight increase of 0.18% compared to CNY 514.76 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 79.79 million, representing a year-on-year growth of 17.27% from CNY 68.04 million[4]. - The net profit after deducting non-recurring gains and losses was CNY 71.16 million, up 10.20% from CNY 64.58 million in the previous year[4]. - The net cash flow from operating activities increased significantly by 144.77% to CNY 28.07 million, compared to CNY 11.47 million in the same period last year[4]. - Total comprehensive income attributable to the parent company's owners increased to 79,793,126.38 from 68,040,684.42, representing a growth of approximately 17.5%[41]. - Basic and diluted earnings per share rose to 0.28 from 0.24, reflecting a 16.7% increase[41]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3.98 billion, a 7.45% increase from CNY 3.70 billion at the end of the previous year[4]. - Total assets increased to ¥3,980,505,214.39 from ¥3,704,414,827.97, representing a growth of approximately 7.43% year-over-year[31]. - Total liabilities rose to ¥1,902,770,717.15, up from ¥1,686,031,905.65, indicating an increase of about 12.85%[31]. - The total liabilities to total assets ratio is approximately 47.8%, indicating a stable leverage position[31]. Revenue and Costs - Operating revenue for the current period was ¥515,706,771.99, slightly up from ¥514,757,244.68, showing a marginal growth of 0.18%[35]. - Total operating costs decreased to ¥438,187,253.22 from ¥445,249,979.39, reflecting a reduction of approximately 1.47%[35]. Research and Development - Research and development expenses increased by 26.54%, driven by accelerated investment in ongoing projects[9]. - Research and development expenses increased to ¥34,242,800.51 from ¥27,060,888.66, representing a growth of approximately 26.93%[35]. - The company is focusing on enhancing its R&D capabilities through various innovative mechanisms to mitigate risks associated with drug development[24]. Shareholder Information - Guangdong Guangrun Group Limited holds 42.49% of the shares, totaling 122,400,000 shares[13]. - Wu Meirong, a natural person, holds 5.90% of the shares, totaling 16,991,040 shares, with 13,592,832 shares pledged[13]. - Li Hanxiong, a natural person, holds 5.75% of the shares, totaling 16,560,000 shares, with 13,248,000 shares pledged[13]. - Guangzhou Fuze Investment Management Center (Limited Partnership) holds 5.62% of the shares, totaling 16,200,000 shares[13]. - The total number of ordinary shareholders at the end of the reporting period is 10,915[13]. Cash Flow - Cash inflow from operating activities totaled 604,375,791.80, up from 569,479,774.31, indicating a growth of about 6.5%[42]. - Cash outflow from investment activities was 867,375,742.98, compared to 714,348,600.84, showing an increase of around 21.5%[45]. - Net cash flow from financing activities decreased to 334,117,705.69 from 469,706,220.31, a decline of about 29%[48]. - The ending cash and cash equivalents balance was 897,727,783.16, slightly down from 898,619,042.35, indicating a decrease of approximately 0.1%[48]. Investments and Subsidiaries - The company completed a capital increase of ¥49,880,660 for its subsidiary, raising its stake in Huannan Vaccine from 52.7077% to 58.9582%[24]. - The company completed an investment of CNY 15 million in a biopharmaceutical investment partnership, marking a significant operational phase[8]. Government Support - The company received government subsidies amounting to CNY 4.18 million, contributing to a significant increase in non-operating income by 5,760.09%[12].

Financial Performance - The company's operating revenue for 2021 was ¥2,199,214,423.42, representing a 31.26% increase compared to ¥1,675,417,058.94 in 2020[35]. - The net profit attributable to shareholders for 2021 was ¥306,915,390.82, a 36.04% increase from ¥225,610,583.46 in 2020[35]. - The net cash flow from operating activities for 2021 was ¥438,100,615.95, up 59.18% from ¥275,221,007.33 in 2020[35]. - The total assets at the end of 2021 reached ¥3,704,414,827.97, a 72.69% increase from ¥2,145,157,902.64 at the end of 2020[35]. - The basic earnings per share for 2021 was ¥1.07, an increase of 37.18% compared to ¥0.78 in 2020[35]. - The company reported a net profit of ¥181,930,128.70 after deducting non-recurring gains and losses, which is a 24.95% increase from ¥145,601,865.03 in 2020[35]. - The company received government subsidies amounting to ¥110,746,384.88 in 2021, compared to ¥90,707,525.88 in 2020[43]. - The weighted average return on equity for 2021 was 15.23%, slightly down from 16.15% in 2020[35]. - The company achieved a total operating revenue of 2,199.21 million yuan in 2021, representing a year-on-year growth of 31.26%[95]. - The company's net profit totaled 306.92 million yuan, reflecting a year-on-year growth of 36.04%[95]. Market Expansion and Development - The company has established a nationwide market network, transitioning from a focus on the South China market to a comprehensive national market development[8]. - The company is navigating market expansion risks due to ongoing healthcare reforms and the dynamic adjustment of national drug lists[8]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[35]. - The company has established a comprehensive national market network, having developed over 8,000 terminal medical institutions in 2021[66]. - The marketing network covers all 30 provincial-level administrative regions, with significant revenue growth in various regions, such as a 142.39% increase in Northeast region[147]. Research and Development - The company has made breakthroughs in its product pipeline, particularly in pediatric and chronic disease medications[8]. - The company is actively enhancing its innovative drug development capabilities through various mechanisms, including independent and collaborative research[8]. - The company has established a new research and development center to foster a highly efficient R&D team[8]. - The company is focusing on the development of recombinant protein vaccines, which are recognized as a mainstream technology direction in the vaccine industry[60]. - The company has established multiple technology innovation platforms for pediatric and chronic disease medications, focusing on high uric acid syndrome and gout treatments[84]. - The R&D team consists of 261 professionals, focusing on innovative drug development in pediatric and chronic disease areas[66]. - The company has developed several innovative drug platforms, including pediatric medication and chronic disease drug formulations, significantly improving its R&D output capabilities[111]. - The company has established a slow disease drug technology platform, with 22 ongoing projects including AR882 and RDH099 sustained-release capsules[139]. - The company has ongoing research and development for innovative drugs including AR882 for gout and AR035 for cancer treatment[198]. Product Development and Approvals - The company has 18 registered pediatric drug products, covering over 70% of diseases affecting children aged 0-14[76]. - The company is currently developing 10 pediatric-specific drugs and 5 pediatric vaccine products, targeting high-incidence diseases such as epilepsy and influenza[76]. - The company has received 13 new drug registration approvals in 2021, ranking among the top 15 in the industry[66]. - The company has obtained 11 new slow disease drug approvals during the reporting period, including valsartan and amlodipine tablets[81]. - The company has launched several new products, including a series of injectable drugs and oral formulations, with approvals received throughout 2021[105]. - The company has applied for 10 invention patents and obtained 16 product registration approvals by the end of the reporting period[96]. - The company has expanded its vaccine pipeline with multiple candidates for flu and respiratory viruses, all receiving production approvals[186]. Quality Assurance and Compliance - The company emphasizes the importance of adhering to GMP and GSP standards in drug production and distribution, with no significant quality incidents reported to date[11]. - The company has not experienced any major product quality disputes or incidents during regulatory inspections[11]. - The company maintains a strong focus on R&D and has established partnerships for resource sharing and mutual benefits in the pharmaceutical sector[152]. - The company emphasizes quality assurance and has a robust production quality management system in place, ensuring stable and controllable product quality[151]. - The company successfully passed various regulatory inspections during the reporting period, ensuring compliance with GMP standards[151]. Financial Investments and Cash Flow - The company reported a debt restructuring gain of 19,505,595.01 yuan, primarily from the restructuring of Kangmei's debt[47]. - The company generated 23,960,000.00 yuan from fair value changes of trading financial assets, mainly from non-financial instruments[47]. - The company received a tax refund of 697,852.70 yuan during the reporting period, contributing to other non-recurring gains[47]. - The company reported a total non-recurring gain of 124,985,262.12 yuan for the period[47]. - The company invested CNY 142,323,018.12 in R&D in 2021, representing 6.47% of its operating revenue[187]. - Operating cash inflows increased by 32.78% to CNY 2,656,180,339.50 in 2021, driven by a 43.97% growth in pharmaceutical product sales[190]. - Financing cash inflows surged by 327.12% to CNY 1,335,115,396.42, attributed to the issuance of convertible bonds and bank loans[191]. Strategic Partnerships and Collaborations - The company has partnered with Lyndra Therapeutics to develop an oral, long-acting, sustained-release formulation for treating opioid use disorder, which has received FDA fast track designation[111]. - The company launched a collaboration with Shenzhen Ruihua Pharmaceutical Technology Co., Ltd. to develop tofacitinib citrate sustained-release tablets[115]. - The company has invested in AI drug development firm Alpha Molecular Technology, focusing on integrating AI and original biotechnology for new drug research[112]. Challenges and Risks - The company faces risks in drug research and development due to the high-tech, high-investment, and long-cycle nature of the pharmaceutical industry[8]. - The company has engaged Everbright Securities as its sponsor for ongoing supervision from August 12, 2020, to December 31, 2023[34]. - The company has established a new gene-engineered vaccine R&D and industrialization platform based on the BEVS system, currently developing 7 products including quadrivalent influenza vaccine and HPV vaccine[140].

Financial Performance - The company's revenue for Q3 2021 reached ¥700,015,238.11, representing a year-on-year increase of 28.83%[6] - Net profit attributable to shareholders for Q3 2021 was ¥170,338,311.84, up 46.66% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥99,637,345.14, reflecting a growth of 33.97% year-on-year[6] - Total operating revenue for the third quarter reached ¥1,653,196,227.48, an increase of approximately 38.4% compared to ¥1,194,068,992.02 in the same period last year[44] - Net profit for the period was ¥264,424,910.75, representing a 34.8% increase from ¥196,101,762.19 in the previous year[48] - Total comprehensive income for the period reached ¥288,298,552.64, a significant increase from ¥196,600,309.29 in the previous period, representing a growth of approximately 46.6%[51] - Basic and diluted earnings per share both increased to ¥1.001 from ¥0.6830, reflecting a growth of 46.5%[51] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥3,178,339,745.13, an increase of 48.16% from the end of the previous year[6] - Total liabilities rose to ¥1,322,763,034.29, up from ¥650,140,117.43, indicating an increase of about 103.5%[44] - The equity attributable to shareholders of the parent company reached ¥1,746,793,712.77, compared to ¥1,484,911,947.52, reflecting a growth of approximately 17.6%[44] - The company's total assets increased to ¥3,178,339,745.13, compared to ¥2,145,157,902.64, marking a growth of approximately 48.2%[44] - The company's long-term equity investments were reported at ¥35 million, with no previous figure available for comparison[38] - The company's non-current financial assets increased significantly to ¥368.20 million from ¥38 million, showing a growth of approximately 867.4%[38] Cash Flow - Cash inflow from operating activities totaled ¥1,894,283,154.74, up from ¥1,337,802,911.48, indicating a year-over-year increase of about 41.5%[55] - Net cash flow from operating activities was ¥243,241,364.84, compared to ¥130,470,475.64 in the previous period, marking an increase of approximately 86.3%[55] - Cash outflow from investing activities was ¥1,716,383,693.55, slightly down from ¥1,767,243,447.82, showing a decrease of about 2.9%[55] - Net cash flow from financing activities was ¥574,332,365.32, a substantial increase from ¥87,010,980.86, reflecting a growth of approximately 560.5%[58] - The ending cash and cash equivalents balance was ¥512,239,494.01, compared to ¥433,269,112.67 in the previous period, representing an increase of about 18.3%[58] Research and Development - R&D expenses increased by 50.25% as the company continued to invest in research and obtained multiple production approvals[17] - The company achieved a significant increase in R&D investment, totaling CNY 99.66 million for the first nine months of 2021, representing a growth of 50.25% year-over-year[32] - Research and development expenses for the quarter were ¥99,664,042.19, an increase from ¥66,334,263.56, representing a year-over-year growth of about 50.3%[44] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,272, with Guangdong Guangrun Group holding 42.50% of shares[18] - The company reported a total of 97,920,000 shares held by Guangdong Guangrun Group Limited, with a commitment to limit share reduction to no more than 20% of total shares held annually[25] - The company has repurchased a total of 3,917,380 shares through a dedicated securities account, with a total repurchase fund of no less than RMB 100 million and not exceeding RMB 200 million[27] - The company plans to unlock 592,200 restricted shares from the 2018 first phase stock incentive plan, with 623,430 shares being repurchased due to unmet performance conditions[27] Market Expansion and Product Development - The company launched 9 new varieties and 11 drug registration approvals as of the report date, which are expected to positively contribute to revenue[12] - The company has entered the biopharmaceutical field through investments in vaccine companies and partnerships for innovative drug development[12] - The company is actively expanding its market presence nationwide, transitioning from a focus on South China to a broader national market strategy[35]